Lobbying disclosures · Lobbying report
BMY: second_quarter 2026 lobbying report
Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.
Follow BMY- Became public
- Jul 20, 2026, 6:14 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 3:00 PM EST
Why this is connected
Legal-name match: BRISTOL-MYERS SQUIBB COMPANY is BRISTOL MYERS SQUIBB CO (https://www.sec.gov/Archives/edgar/data/14272/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/c6c96252-6d0b-4146-8b55-e7fafff3f08a/","filing_uuid":"c6c96252-6d0b-4146-8b55-e7fafff3f08a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/c6c96252-6d0b-4146-8b55-e7fafff3f08a/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey Miller","dt_posted":"2026-07-20T18:14:00-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"P.O. Box 625","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Buda","registrant_state":"TX","registrant_zip":"78610","registrant":{"id":401104313,"url":"https://lda.gov/api/v1/registrants/401104313/","house_registrant_id":null,"name":"MILLER STRATEGIES, LLC","description":"strategic public affairs","address_1":"P.O. Box 625","address_2":null,"address_3":null,"address_4":null,"city":"Buda","state":"TX","state_display":"Texas","zip":"78610","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JEFFREY MILLER","contact_telephone":"+1 202-434-8242","dt_updated":"2026-07-30T15:40:39.312430-04:00"},"client":{"id":69032,"url":"https://lda.gov/api/v1/clients/69032/","client_id":69032,"name":"BRISTOL-MYERS SQUIBB COMPANY","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-09-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BMY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 11, 2026$15K–$50K
Rep. Mike Kelly (R-PA-16)
Sold Bristol-Myers Squibb Company BMY
$15K–$50K · Traded May 7, 2026 · disclosed Jun 11, 2026 · Spouse
Got $3K from the company’s PAC - Feb 6, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Sold Bristol-Myers Squibb Company BMY
$15K–$50K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 15, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Dec 18, 2025 · disclosed Jan 15, 2026 · Joint
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Apr 28, 2025 · disclosed Jan 13, 2026 · filed 260 days later
Got $2K from the company’s PAC - Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 23, 2024 · disclosed Jan 13, 2026 · filed 447 days later
Got $2K from the company’s PAC
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.